Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial.
Abstract | IMPORTANCE: OBJECTIVE: DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, active-controlled superiority trial that enrolled 13,229 patients with NSTE-ACS and a planned early invasive strategy, at 568 active sites in 55 countries and conducted between April 2010 and February 2013. A planned interim analysis was conducted for otamixaban dose selection. INTERVENTIONS: MAIN OUTCOMES AND MEASURES: The primary efficacy outcome was the composite of all-cause death or new myocardial infarction through day 7. RESULTS: Rates of the primary efficacy outcome were 5.5% (279 of 5105 patients) randomized to receive otamixaban and 5.7% (310 of 5466 patients) randomized to receive unfractionated heparin plus eptifibatide (adjusted relative risk, 0.99 [95% CI, 0.85-1.16]; P = .93). There were no differences for the secondary end points, including procedural thrombotic complications. The primary safety outcome of Thrombosis in Myocardial Infarction major or minor bleeding through day 7 was increased by otamixaban (3.1% vs 1.5%; relative risk, 2.13 [95% CI, 1.63-2.78]; P < .001). Results were consistent across prespecified subgroups. CONCLUSIONS AND RELEVANCE: TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01076764.
|
Authors | Philippe Gabriel Steg, Shamir R Mehta, Charles V Pollack Jr, Christoph Bode, Marc Cohen, William J French, James Hoekstra, Sunil V Rao, Witold Ruzyllo, Juan M Ruiz-Nodar, Manel Sabaté, Petr Widimsky, Robert Gabor Kiss, Jose Luis Navarro Estrada, Hanoch Hod, Prafulla Kerkar, Sema Guneri, Murat Sezer, Mikhail Ruda, José Carlos Nicolau, Claudio Cavallini, Iftikhar Ebrahim, Ivo Petrov, Jae-Hyung Kim, Myung-Ho Jeong, Gabriel Arturo Ramos Lopez, Peep Laanmets, Frantisek Kovar, Christophe Gaudin, Karen C Fanouillere, Pascal Minini, Elaine B Hoffman, Angele Moryusef, Stephen D Wiviott, Marc S Sabatine, TAO Investigators |
Journal | JAMA
(JAMA)
Vol. 310
Issue 11
Pg. 1145-55
(Sep 18 2013)
ISSN: 1538-3598 [Electronic] United States |
PMID | 23995608
(Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anticoagulants
- Cyclic N-Oxides
- Factor Xa Inhibitors
- Peptides
- Platelet Glycoprotein GPIIb-IIIa Complex
- Pyridines
- Heparin
- Eptifibatide
- otamixaban
|
Topics |
- Acute Coronary Syndrome
(complications, drug therapy)
- Adult
- Aged
- Aged, 80 and over
- Anticoagulants
(adverse effects, therapeutic use)
- Cause of Death
- Cyclic N-Oxides
(adverse effects, therapeutic use)
- Double-Blind Method
- Eptifibatide
- Factor Xa Inhibitors
- Female
- Hemorrhage
(chemically induced)
- Heparin
(therapeutic use)
- Humans
- Infusions, Intravenous
- Injections, Intravenous
- Male
- Middle Aged
- Myocardial Infarction
(etiology, prevention & control)
- Peptides
(therapeutic use)
- Percutaneous Coronary Intervention
- Platelet Glycoprotein GPIIb-IIIa Complex
(antagonists & inhibitors)
- Pyridines
(adverse effects, therapeutic use)
- Risk
- Survival Analysis
- Treatment Outcome
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|